Medicinal Mushrooms Market Size, Share, and Growth Forecast 2026 - 2033

The global medicinal mushrooms market size is likely to be valued at US$39.4 billion in 2026 and is estimated to reach US$79.2 billion by 2033, growing at a CAGR of 10.5% during the forecast period from 2026 to 2033, driven by the rising use of reishi, lion’s mane, cordyceps, turkey tail, and other mushrooms in immunity, cognition, stress-support, and digestive-health formulations. Expansion into coffee, gummies, beverages, powders, and other convenient formats is making medicinal mushrooms easy to include in everyday diets.

Driver - Increasing Interest in Immune and Stress Support to Push Demand

Medicinal mushrooms are benefiting from consumer interest in products positioned around immunity, stress response, cognition, and everyday wellness. Reishi contains beta-glucan polysaccharides and triterpenes, while other mushrooms provide distinct polysaccharides and secondary metabolites. Scientific interest in these compounds is strengthening the credibility of the category.

For example, a ClinicalTrials.gov-listed study updated in 2025 is comparing Agaricus, reishi, and turkey tail against placebo and assessing cytokines, immune-cell activity, and immune surveillance. The National Cancer Institute also describes extensive research on mushroom polysaccharides and immune pathways, mainly turkey tail-derived PSK. This expanding evidence base is encouraging manufacturers to develop more standardized extracts and species-specific products rather than relying only on traditional wellness positioning.

Everyday Food Formats to Make Functional Mushrooms Easy to Adopt

Medicinal mushrooms are becoming easier to consume because brands are moving them beyond capsules and tinctures. Mushroom coffee, cocoa, gummies, drink powders, creamers, teas, and functional beverages allow consumers to add these ingredients to habits they already follow. This lowers one of the category's traditional barriers, i.e., unfamiliar taste and preparation.

Laird Superfood demonstrated this shift in May 2025 by adding six organic mushroom powders, including lion’s mane, reishi, turkey tail, oyster mushroom, and targeted botanical blends. Om Mushrooms also expanded its mushroom gummy range with Cordyceps and Reishi variants in 2025. In the U.K., Marks & Spencer introduced drinks incorporating lion’s mane and reishi. Such launches are moving medicinal mushrooms closer to everyday functional nutrition.

Restraint - Medication Interactions May Limit Unsupervised Use of Some Mushroom Products

Safety concerns can restrict medicinal mushroom use among people taking prescription medicines. Mushroom extracts contain concentrated bioactive compounds, so their effects can differ from eating ordinary culinary mushrooms. Reishi is an important example. Memorial Sloan Kettering Cancer Center advises people using blood thinners such as warfarin to discuss reishi with their healthcare provider because it can increase bleeding risk. It also notes possible interactions with immunosuppressants and some drug-metabolizing enzymes.

This creates a challenge for supplement companies because various potential users are older adults who may already take several medicines. Products positioned around immunity can create additional concerns for people receiving immunosuppressive treatment. Clear dosage information, interaction warnings, standardized extracts, and superior clinical safety data are hence important for expanding medicinal mushroom use responsibly.

Opportunity - Microbiome Research to Open New Uses for Mushroom-based Prebiotics

Gut health could become one of the most valuable new applications for medicinal mushroom ingredients. Fungal polysaccharides can act as fermentable substrates for intestinal microbes rather than being completely digested in the upper digestive tract. A 2026 review in npj Science of Food concluded that medicinal and edible fungal polysaccharides can regulate gut microbiota, immunity, and metabolic processes, supporting their development as prebiotic ingredients.

Another 2025 study found that Poria cocos polysaccharides increased beneficial Lactobacillus and Bifidobacterium, increased short-chain fatty acids, and reduced several potentially harmful bacterial groups in an in-vitro human fecal fermentation model. These findings create opportunities for mushroom-based synbiotics, digestive supplements, nutrition powders, functional foods, and microbiome-focused formulations.

Cancer-support Research to Create Scope for Standardized Mushroom Compounds

Medicinal mushrooms have a promising opportunity as sources of standardized compounds studied alongside conventional cancer treatment. Turkey tail provides the strongest precedent. The National Cancer Institute reports that PSK, a protein-bound polysaccharide obtained from turkey tail, has been used as an approved adjunct cancer product in Japan. Clinical research has examined PSK alongside chemotherapy and radiotherapy across several cancers.

Research is continuing with more precisely defined populations. Mayo Clinic's Phase II trial is evaluating turkey tail in postmenopausal women with HER2-negative, estrogen-receptor-positive breast cancer before surgery and remained listed as recruiting following a March 2026 update. This creates longer-term opportunities for purified beta-glucans, polysaccharides, and other standardized fungal compounds, although pharmaceutical claims will require rigorous clinical evidence and regulatory approval.

Source Insights

Wild-harvested mushrooms are predicted to lead with a share of about 67.4% in 2026, because they are strongly associated with their natural ecological origin. This is relevant for species such as chaga, which naturally develops on birch trees, and wild cordyceps, whose natural growth conditions are difficult to reproduce. Traditional users also associate mushrooms collected from forests with authenticity and the historical medicinal practices of China, Japan, Siberia, and other regions. Wild products can further command rising interest when buyers seek naturally occurring chemical profiles shaped by environmental stress, tree hosts, climate, and long growth periods.

Cultivated mushrooms are estimated to be the fastest-growing segment in the forecast period, as manufacturers can control the growing substrate, humidity, temperature, harvest stage, species identity, and contamination risk. This makes it easier to produce uniform raw material for capsules, extracts, beverages, and pharmaceutical research. DXN, for example, operates its own cultivation and research & development infrastructure for mushroom-based nutraceutical products, while M2 Ingredients supplies U.S.-cultivated organic mushroom ingredients for commercial formulations. Cultivation is especially important when companies need specific bioactive compounds. Lion’s mane provides a good example.

Application Insights

Nutraceuticals are anticipated to dominate with a share of around 40.2% in 2026, as medicinal mushrooms already fit naturally into the dietary supplement model. Reishi, lion’s mane, cordyceps, turkey tail, chaga, and maitake can be processed into powders, standardized extracts, capsules, gummies, tinctures, and drink mixes without requiring the lengthy drug-development pathway associated with pharmaceuticals. The application is further supported by the wide range of wellness functions being investigated around mushroom compounds. Beta-glucans are associated with immune modulation, while lion’s mane is receiving attention for neuroactive compounds, including erinacines.

Pharmaceuticals are expected to remain in the second position in 2026 because researchers are moving beyond broad traditional claims and studying defined mushroom compounds, mechanisms, doses, and clinical applications. Turkey tail is a prominent historical example.

The U.S. National Cancer Institute notes that polysaccharide-K, or PSK, derived from turkey tail, has been used as an approved adjunct to cancer therapy in Japan. Medicinal mushroom products have also been used alongside conventional cancer treatment in parts of Asia for decades. Pharmaceutical growth, hence, is being driven less by generic mushroom powders and more by purified polysaccharides, standardized beta-glucans, spores, metabolites, and other defined molecules.

North America Medicinal Mushrooms Market Trends

North America is predicted to dominate globally in 2026 with a share of approximately 45.3%, because functional mushrooms have moved from specialist herbal stores into mainstream supplements, beverages, coffee alternatives, powders, gummies, and performance nutrition.

The region also has an unusually developed ecosystem of mushroom specialists, including Real Mushrooms, Fungi Perfecti/Host Defense, Nammex, M2 Ingredients, and Four Sigmatic. Innovation is now focused on product quality rather than simply adding mushroom names to labels. The U.S. research network provides another advantage. NIH-linked resources cover mushroom supplement use, while Mayo Clinic and other institutions are conducting clinical research into mushrooms such as turkey tail.

U.S. Medicinal Mushrooms Market Trends

A share of nearly 56.9% is expected to be held by the U.S. in 2026 in North America, as mushroom ingredients are moving into categories that consumers already purchase frequently. Coffee, drink powders, gummies, cognitive supplements, sports products, and stress-support formulations are providing more consumption occasions than traditional capsules alone. Laird Superfood's May 2025 introduction of six additional mushroom powders demonstrates this diversification. The products included individual lion’s mane, reishi, turkey tail, and oyster powders, as well as formulations combining mushrooms with other botanicals. Domestic supply capability is further improving.

Asia Pacific Medicinal Mushrooms Market Trends

Asia Pacific is anticipated to be the fastest-growing region globally in 2026 with a share of around 23.3%, as it combines an established medicinal tradition with rapidly modernizing supplement, functional food, and pharmaceutical industries.

Reishi, shiitake, cordyceps, turkey tail, and related fungi already have strong cultural recognition in China, Japan, Korea, and other Asian countries. The National Cancer Institute notes that more than 100 medicinal mushroom species are used in Asia and that mushroom-derived adjuncts have a long clinical history in countries such as Japan and China. The region is now adding modern cultivation, extraction, and standardized product development to this traditional base. This makes consumer education easier than in markets where medicinal mushrooms are relatively new.

China Medicinal Mushrooms Market Trends

China will likely lead in Asia Pacific in 2026 with a share of about 33.6%, supported by medicinal mushroom expansion because fungi such as lingzhi, or reishi, are already deeply embedded in Traditional Chinese Medicine. Recent research continues to examine Ganoderma pharmacology, polysaccharides, triterpenes, and other bioactive compounds. A 2025 review indexed by PubMed described reishi as a medicinal fungus used in Asia for more than two millennia. China is also increasing organized cultivation. In 2025, Guiyang and Gui’an planned 10,000 mu of under-forest edible mushroom production and continued developing demonstration bases and enterprises around forest-derived industries.

India Medicinal Mushrooms Market Trends

In 2026, India is projected to account for a share of just about 25.4% in Asia Pacific, due to its wide expansion of nutraceuticals, preventive wellness, Ayurveda-adjacent products, and natural functional ingredients. Lion’s mane, cordyceps, reishi, and mixed-mushroom products are increasingly positioned alongside familiar adaptogenic ingredients such as ashwagandha. A key regulatory framework further helps organized companies enter the category. FSSAI regulates health supplements, nutraceuticals, functional foods, prebiotic foods, and novel foods under its health supplement and nutraceutical framework. This creates a formal route for companies developing functional ingredient products rather than relying entirely on unregulated traditional claims.

Europe Medicinal Mushrooms Market Trends

Europe will likely see decent growth in the forecast period with a share of roughly 18.5% in 2026 globally, because demand for natural wellness, organic ingredients, and functional foods is strong, but novel-food rules create a higher compliance barrier for less-established mushroom ingredients and preparations. The European Commission maintains a Novel Food Status Catalogue that manufacturers can use to assess whether a particular food or ingredient has a history of significant consumption before the relevant regulatory cutoff. This is important for medicinal mushrooms because the regulatory position can differ depending on species, mushroom part, extract, or production method.

Germany Medicinal Mushrooms Market Trends

Germany is predicted to register a substantial share of approximately 39.7% in 2026 in Europe, as functional mushrooms fit closely with the country's established organic food, natural health, and dietary supplement sectors. Innovation is moving toward convenient formulations, including drink mixes, extracts, and tinctures. In January 2025, Finnish functional mushroom producer KÄÄPÄ Mushrooms expanded into Germany through a distribution partnership with AnnexGlobal.

The initial German portfolio included organic shiitake, lion’s mane, reishi, and chaga tinctures and extract powders. The mushrooms were cultivated and processed in Finland, and the producer held FSSC 22000 food-safety certification.

U.K. Medicinal Mushrooms Market Trends

A share of nearly 24.2% is predicted to be held by the U.K. in 2026 in Europe, because functional mushrooms are moving into mainstream food, beauty, and wellness retail. In January 2025, Marks & Spencer introduced its YAY! Mushrooms beverage range in collaboration with the Royal Botanic Gardens, Kew. The range incorporated lion’s mane and reishi into ready-to-consume drinks, bringing functional mushrooms to a much broader retail audience. Domestic supplement innovation is also increasing.

Scottish company Love Mushrooms launched an expanded lion’s mane supplement range in 2025, while Revive Collagen introduced formulations combining lion’s mane, reishi, and chaga with liquid collagen.

The global medicinal mushrooms market is fragmented. But it is gradually consolidating as established supplement companies, specialist mushroom growers, ingredient suppliers, and functional food brands expand through acquisitions, partnerships, and new product launches. Specialist companies such as Fungi Perfecti/Host Defense, Real Mushrooms, Nammex, M2 Ingredients/Om Mushrooms, DXN Holdings, and Hifas da Terra compete through cultivation expertise, extraction technology, organic certification, beta-glucan standardization, and species-specific formulations.

Consumer-facing companies, including Four Sigmatic, are taking a different route by making lion’s mane, chaga, reishi, and cordyceps easier to consume through coffee, powders, beverages, gummies, and daily wellness blends. Nammex, for example, emphasizes extracts made entirely from mushroom fruiting bodies and tests them for compounds such as beta-glucans. Competition is also shifting from simply selling mushroom powder toward proving exactly what the product contains. Species identity, fruiting body versus mycelium, extraction ratio, beta-glucan concentration, erinacine content, organic certification, and heavy-metal testing are becoming key differentiators.

Key Industry Developments

• In June 2026, Real Mushrooms launched Real Mycelium, a grain-free lion’s mane mycelium supplement formulated to provide a verified 5 mg dose of Erinacine A per serving. The company positioned the product as an alternative to mycelium-on-grain formulations with poorly defined concentrations of the bioactive compound.
• In February 2026, Real Mushrooms announced the acquisition of Mushroom Science, bringing together two specialist functional mushroom businesses with an emphasis on extraction quality, ingredient potency, scientific evidence, and transparent labeling.
• In September 2025, a clinical trial sponsored by Natural Immune Systems was listed as recruiting to compare the short-term immune effects of Agaricus blazei, reishi, and turkey tail against placebo. The study was assessing cytokine responses, immune-cell activity, trafficking, and immune surveillance in healthy participants.